NZ724424A - Pyrimidine derivatives for the treatment of bacterial diseases - Google Patents
Pyrimidine derivatives for the treatment of bacterial diseasesInfo
- Publication number
- NZ724424A NZ724424A NZ724424A NZ72442413A NZ724424A NZ 724424 A NZ724424 A NZ 724424A NZ 724424 A NZ724424 A NZ 724424A NZ 72442413 A NZ72442413 A NZ 72442413A NZ 724424 A NZ724424 A NZ 724424A
- Authority
- NZ
- New Zealand
- Prior art keywords
- treatment
- pyrimidine derivatives
- bacterial diseases
- compounds
- bacterial
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title abstract 2
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12166140 | 2012-04-30 | ||
| NZ700507A NZ700507A (en) | 2012-04-30 | 2013-04-30 | Pyrimidine derivatives for the treatment of bacterial diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ724424A true NZ724424A (en) | 2018-02-23 |
Family
ID=48430690
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ724424A NZ724424A (en) | 2012-04-30 | 2013-04-30 | Pyrimidine derivatives for the treatment of bacterial diseases |
| NZ700507A NZ700507A (en) | 2012-04-30 | 2013-04-30 | Pyrimidine derivatives for the treatment of bacterial diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ700507A NZ700507A (en) | 2012-04-30 | 2013-04-30 | Pyrimidine derivatives for the treatment of bacterial diseases |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9725432B2 (enExample) |
| EP (1) | EP2938599B1 (enExample) |
| JP (2) | JP6349303B2 (enExample) |
| KR (1) | KR102186851B1 (enExample) |
| CN (1) | CN104487425B (enExample) |
| AR (1) | AR090880A1 (enExample) |
| AU (1) | AU2013255843B2 (enExample) |
| BR (1) | BR112014026776B1 (enExample) |
| CA (1) | CA2868930C (enExample) |
| EA (1) | EA030899B1 (enExample) |
| ES (1) | ES2676189T3 (enExample) |
| IN (1) | IN2014MN02363A (enExample) |
| MX (1) | MX358189B (enExample) |
| NZ (2) | NZ724424A (enExample) |
| TW (1) | TWI598099B (enExample) |
| WO (1) | WO2013164337A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR090880A1 (es) * | 2012-04-30 | 2014-12-10 | Janssen R & D Ireland | Derivados de pirimidina |
| WO2019121352A1 (en) * | 2017-12-20 | 2019-06-27 | Basf Se | Herbicidal pyrimidine compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887870B1 (en) * | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
| AU2003214110A1 (en) * | 2002-03-15 | 2003-09-29 | Ciba Specialty Chemicals Holding Inc. | 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces |
| DE102004003493A1 (de) | 2004-01-23 | 2005-08-11 | Bayer Cropscience Ag | 5-Phenylpyrimidine |
| EP1871762A2 (en) * | 2005-04-18 | 2008-01-02 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| AU2009208712B2 (en) * | 2008-02-01 | 2013-03-14 | Orchid Chemicals & Pharmaceuticals Limited | Novel heterocycles |
| CA2776849A1 (en) * | 2009-11-18 | 2011-05-26 | Fab Pharma S.A.S. | Novel heterocyclic acrylamides and their use as pharmaceuticals |
| WO2011060976A1 (en) * | 2009-11-20 | 2011-05-26 | Universite De Liege | Tryptamine-derived compounds as antibacterial agents |
| JP5697685B2 (ja) * | 2009-12-18 | 2015-04-08 | バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ | 三環式抗生物質 |
| AR090880A1 (es) * | 2012-04-30 | 2014-12-10 | Janssen R & D Ireland | Derivados de pirimidina |
-
2013
- 2013-04-29 AR ARP130101454A patent/AR090880A1/es active IP Right Grant
- 2013-04-29 TW TW102115187A patent/TWI598099B/zh not_active IP Right Cessation
- 2013-04-30 CN CN201380022591.6A patent/CN104487425B/zh active Active
- 2013-04-30 US US14/397,501 patent/US9725432B2/en active Active
- 2013-04-30 EA EA201491992A patent/EA030899B1/ru not_active IP Right Cessation
- 2013-04-30 CA CA2868930A patent/CA2868930C/en active Active
- 2013-04-30 EP EP13722329.3A patent/EP2938599B1/en active Active
- 2013-04-30 AU AU2013255843A patent/AU2013255843B2/en not_active Ceased
- 2013-04-30 BR BR112014026776-6A patent/BR112014026776B1/pt not_active IP Right Cessation
- 2013-04-30 WO PCT/EP2013/058980 patent/WO2013164337A1/en not_active Ceased
- 2013-04-30 JP JP2015509418A patent/JP6349303B2/ja active Active
- 2013-04-30 ES ES13722329.3T patent/ES2676189T3/es active Active
- 2013-04-30 NZ NZ724424A patent/NZ724424A/en not_active IP Right Cessation
- 2013-04-30 KR KR1020147029515A patent/KR102186851B1/ko not_active Expired - Fee Related
- 2013-04-30 NZ NZ700507A patent/NZ700507A/en not_active IP Right Cessation
- 2013-04-30 IN IN2363MUN2014 patent/IN2014MN02363A/en unknown
- 2013-04-30 MX MX2014013165A patent/MX358189B/es active IP Right Grant
-
2017
- 2017-08-04 US US15/668,773 patent/US10221157B2/en active Active
-
2018
- 2018-03-20 JP JP2018052573A patent/JP6622839B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA030383B9 (ru) | Бициклически замещённые урацилы, способы их получения, их применение, лекарственное средство и способ лечения с их применением | |
| MY164776A (en) | Heterocyclic compound | |
| PH12013500301A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| PH12015501585A1 (en) | Manufacturing process for pyrimidine derivatives | |
| MD20140063A2 (ro) | Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV | |
| TN2013000434A1 (en) | Novel imidazole derivatives useful for the treatment of arthritis | |
| TN2014000122A1 (en) | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | |
| AU2011286276A8 (en) | Substituted Biphenylene Compounds and methods of use thereof for the treatment of viral diseases | |
| PH12014501417A1 (en) | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | |
| PH12013501600A1 (en) | Novel heterocyclic derivatives | |
| MY171831A (en) | Novel fused pyrimidine compound or salt thereof | |
| MD20160105A2 (ro) | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide | |
| AU2018253590A1 (en) | Imidazopyridazine compounds | |
| IN2014CN04449A (enExample) | ||
| PH12015500111A1 (en) | Difluorolactam compositions for ep4-mediated osteo related diseases and conditions | |
| MX2013008164A (es) | Proceso para hacer inhibidores de girasa y topoisomerasa iv. | |
| IN2013DN02555A (enExample) | ||
| PH12014501943A1 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
| MD20160111A2 (ro) | Derivaţi diheterociclici legaţi de cicloalchil | |
| TN2015000095A1 (en) | Macrolide derivatives, preparation thereof and therapeutic use thereof | |
| UA104102C2 (en) | α-CRYSTALLINE FORM OF CARBABENZPYRIDE | |
| NZ700507A (en) | Pyrimidine derivatives for the treatment of bacterial diseases | |
| GB2527958A (en) | Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents | |
| TN2013000052A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| TN2013000122A1 (en) | Oxadiazole inhibitors of leukotriene production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2020 BY CPA GLOBAL Effective date: 20190314 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2021 BY CPA GLOBAL Effective date: 20200319 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2022 BY CPA GLOBAL Effective date: 20210318 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2023 BY CPA GLOBAL Effective date: 20220318 |
|
| LAPS | Patent lapsed |